Larry Biegelsen
Stock Analyst at Wells Fargo
(3.58)
# 772
Out of 5,182 analysts
375
Total ratings
51.7%
Success rate
4.89%
Average return
Main Sectors:
Stocks Rated by Larry Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Overweight | $94 → $75 | $59.95 | +25.10% | 17 | Apr 23, 2026 | |
| JNJ Johnson & Johnson | Maintains: Overweight | $240 → $263 | $225.34 | +16.71% | 16 | Apr 15, 2026 | |
| MMED MiniMed Group | Initiates: Overweight | $26 | $12.92 | +101.24% | 1 | Mar 31, 2026 | |
| HTFL HeartFlow | Maintains: Overweight | $38 → $35 | $31.73 | +10.31% | 2 | Mar 19, 2026 | |
| AVR Anteris Technologies Global | Initiates: Overweight | $16 | $5.66 | +182.69% | 1 | Mar 11, 2026 | |
| TFX Teleflex | Maintains: Equal-Weight | $116 → $130 | $135.07 | -3.75% | 10 | Feb 27, 2026 | |
| MMSI Merit Medical Systems | Downgrades: Equal-Weight | $95 → $78 | $67.43 | +15.68% | 13 | Feb 26, 2026 | |
| ALC Alcon | Upgrades: Overweight | $88 → $97 | $76.01 | +27.61% | 10 | Feb 26, 2026 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $18 | $15.88 | +13.35% | 10 | Feb 19, 2026 | |
| AXGN Axogen | Initiates: Overweight | $40 | $39.39 | +1.55% | 1 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $135 | $122.07 | +10.59% | 18 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $85 | $61.41 | +38.41% | 11 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $145 → $70 | $55.07 | +27.11% | 16 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $93 → $98 | $92.59 | +5.84% | 11 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $96 → $100 | $83.46 | +19.82% | 19 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $97 | $70.48 | +37.63% | 6 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $374 | $327.98 | +14.03% | 20 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $22.23 | +25.96% | 3 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $72 → $82 | $64.34 | +27.45% | 20 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $114 | $82.92 | +37.48% | 19 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $452 → $456 | $329.01 | +38.60% | 17 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $19.82 | -29.36% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $10 | $7.29 | +37.17% | 16 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $599 → $600 | $470.99 | +27.39% | 21 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $0.68 → $0.85 | $1.30 | -34.62% | 6 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $3 | $1.28 | +134.38% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $24 | $18.49 | +29.80% | 17 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $40 → $15 | $12.48 | +16.19% | 18 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $17.25 | -1.45% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $49 | $10.69 | +358.37% | 2 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $136 | $92.80 | +46.55% | 21 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $70 | $93.70 | -25.29% | 7 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $270 | $150.22 | +79.74% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $84.11 | - | 2 | Nov 2, 2017 |
Boston Scientific
Apr 23, 2026
Maintains: Overweight
Price Target: $94 → $75
Current: $59.95
Upside: +25.10%
Johnson & Johnson
Apr 15, 2026
Maintains: Overweight
Price Target: $240 → $263
Current: $225.34
Upside: +16.71%
MiniMed Group
Mar 31, 2026
Initiates: Overweight
Price Target: $26
Current: $12.92
Upside: +101.24%
HeartFlow
Mar 19, 2026
Maintains: Overweight
Price Target: $38 → $35
Current: $31.73
Upside: +10.31%
Anteris Technologies Global
Mar 11, 2026
Initiates: Overweight
Price Target: $16
Current: $5.66
Upside: +182.69%
Teleflex
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $116 → $130
Current: $135.07
Upside: -3.75%
Merit Medical Systems
Feb 26, 2026
Downgrades: Equal-Weight
Price Target: $95 → $78
Current: $67.43
Upside: +15.68%
Alcon
Feb 26, 2026
Upgrades: Overweight
Price Target: $88 → $97
Current: $76.01
Upside: +27.61%
Bausch + Lomb
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $15.88
Upside: +13.35%
Axogen
Feb 19, 2026
Initiates: Overweight
Price Target: $40
Current: $39.39
Upside: +1.55%
Feb 18, 2026
Maintains: Overweight
Price Target: $122 → $135
Current: $122.07
Upside: +10.59%
Feb 13, 2026
Maintains: Overweight
Price Target: $93 → $85
Current: $61.41
Upside: +38.41%
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $145 → $70
Current: $55.07
Upside: +27.11%
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $93 → $98
Current: $92.59
Upside: +5.84%
Feb 11, 2026
Maintains: Overweight
Price Target: $96 → $100
Current: $83.46
Upside: +19.82%
Feb 5, 2026
Maintains: Overweight
Price Target: $95 → $97
Current: $70.48
Upside: +37.63%
Jan 15, 2026
Downgrades: Equal-Weight
Price Target: $374
Current: $327.98
Upside: +14.03%
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $28
Current: $22.23
Upside: +25.96%
Dec 5, 2025
Maintains: Equal-Weight
Price Target: $72 → $82
Current: $64.34
Upside: +27.45%
Nov 19, 2025
Maintains: Overweight
Price Target: $100 → $114
Current: $82.92
Upside: +37.48%
Nov 14, 2025
Maintains: Overweight
Price Target: $452 → $456
Current: $329.01
Upside: +38.60%
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $19.82
Upside: -29.36%
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $7.29
Upside: +37.17%
Oct 22, 2025
Maintains: Overweight
Price Target: $599 → $600
Current: $470.99
Upside: +27.39%
Aug 15, 2025
Maintains: Equal-Weight
Price Target: $0.68 → $0.85
Current: $1.30
Upside: -34.62%
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.28
Upside: +134.38%
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $33 → $24
Current: $18.49
Upside: +29.80%
Jul 25, 2025
Downgrades: Equal-Weight
Price Target: $40 → $15
Current: $12.48
Upside: +16.19%
Jan 30, 2025
Maintains: Overweight
Price Target: $13 → $17
Current: $17.25
Upside: -1.45%
Dec 5, 2023
Upgrades: Overweight
Price Target: $40 → $49
Current: $10.69
Upside: +358.37%
Apr 5, 2023
Maintains: Overweight
Price Target: $140 → $136
Current: $92.80
Upside: +46.55%
May 11, 2022
Maintains: Overweight
Price Target: $80 → $70
Current: $93.70
Upside: -25.29%
Apr 8, 2020
Maintains: Overweight
Price Target: $279 → $270
Current: $150.22
Upside: +79.74%
Nov 2, 2017
Upgrades: Outperform
Price Target: n/a
Current: $84.11
Upside: -